Andrew is an academic physician and researcher with more than three decades of experience at leading institutes in the UK and USA. He is the President-Elect of the Vascular, Lipid & Metabolic Section of the Royal Society of Medicine. His clinical focus is the spectrum of cardiometabolic disorders as prominent precursors of vascular disease. Complementing his broad clinical perspective is a range of research expertise that includes pre-clinical and early-phase clinical drug development (as Senior Research Fellow, ProSciento, San Diego, USA), mechanistic clinical trials and epidemiology (the latter gained during a British Heart Foundation International Research Fellowship at the University of California San Diego, USA where he holds a teaching position). He has made several pioneering contributions to translational medicine that have become established therapies. Andrew was the Director of the Institute for Translational Medicine at the University of Buckingham, UK where he was also Professor of Endocrinology & Metabolism and Director of the Clore Life Sciences laboratory. He currently holds the position of visiting Professor of Medical Science at the Institute for Cardiovascular & Metabolic Research, University of Reading, UK. Beyond pharmacotherapeutics he has long recognised that psychological and behavioral factors are barriers to best outcomes in long-term self-managed disorders and that novel approaches are required to span the translational medicine gap between clinical trials and real world practice.